Leading minds of tomorrow recognized today

April 28, 2003

The American Psychiatric Association (APA) and AstraZeneca announced today the launch of their 2003 'Young Minds in Psychiatry International Awards Programme', an annual commitment by the two organisations to recognize and support promising young psychiatrists from across the globe.

Four unrestricted career development awards of $45,000 (USD) will be available to psychiatry researchers working in the fields of bipolar disorder and schizophrenia. The winners will also be invited to attend an award ceremony at the APA's Young Investigators meeting in New York held as part of their annual congress in May 2004.

Building on the success of the first Young Minds in Psychiatry Awards Programme held in 2002, Darrel Regier, MD, Executive Director of APIRE (American Psychiatric Institute for Research and Education) commented, "The quality of the applications received in 2002 was outstanding and we are pleased to be collaborating with AstraZeneca again this year to provide this vital career development support to young psychiatry researchers."

Nigel Doran, Global Marketing Director, AstraZeneca remarked, "We are dedicated to providing medicines that can make a real impact on the lives of people with disorders of the Central Nervous System. These awards will support innovative research and career development in this specialised field and will ultimately lead to improved treatment options for patients."

To apply for a Young Minds in Psychiatry Award, candidates are requested to submit a proposal of scientific merit demonstrating academic promise and how winning an Award will assist in the advancement of their career. Proposals can cover a range of activities including: research, educational efforts, travel, salary support and materials. All applications will be reviewed by the APIRE and a panel of distinguished psychiatrists.

The closing date for the 2003 APA/AstraZeneca Young Minds in Psychiatry Awards Programme is October 14, 2003.
Notes to Editors:
Further information can be found at http://www.psych.org/res_res/youngminds_announce.cfm or www.astrazeneca.com/youngminds. All applicants must have completed their psychiatric residency within the last five years. The APA/AstraZeneca Young Minds in Psychiatry Awards Programme has evolved from the Young Minds in CNS Program, previously run by AstraZeneca alone.

American Psychiatric Association
The American Psychiatric Association is a national medical specialty society, founded in 1844, whose 38,000 physician members specialize in the diagnosis, treatment and prevention of mental illnesses including substance use disorders.

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the top five pharmaceutical companies in the world with leading positions in sales of gastrointestinal, oncology, anaesthesia (including pain management), cardiovascular, central nervous system (CNS) and respiratory products. In CNS, AstraZeneca is dedicated to providing medicines, which have the potential to change patients' lives. The company's investments in research are aimed toward developing solutions - medicines with greater effectiveness and fewer side effects.

Shire Health International

Related Schizophrenia Articles from Brightsurf:

Schizophrenia: When the thalamus misleads the ear
Scientists at the University of Geneva (UNIGE) and the Synapsy National Centre of Competence in Research (NCCR) have succeeded in linking the onset of auditory hallucinations - one of the most common symptoms of schizophrenia - with the abnormal development of certain substructures of a region deep in the brain called the thalamus.

Unlocking schizophrenia
New research, led by Prof. LIU Bing and Prof. JIANG Tianzi from the Institute of Automation of the Chinese Academy of Sciences and their collaborators have recently developed a novel imaging marker that may help in the personalized medicine of psychiatric disorders.

Researchers discover second type of schizophrenia
In a study of more than 300 patients from three continents, over one third had brains that looked similar to healthy people.

New clues into the genetic origins of schizophrenia
The first genetic analysis of schizophrenia in an ancestral African population, the South African Xhosa, appears in the Jan.

Dietary supplement may help with schizophrenia
A dietary supplement, sarcosine, may help with schizophrenia as part of a holistic approach complementing antipsychotic medication, according to a UCL researcher.

Schizophrenia: Adolescence is the game-changer
Schizophrenia may be related to the deletion syndrome. However, not everyone who has the syndrome necessarily develops psychotic symptoms.

Study suggests overdiagnosis of schizophrenia
In a small study of patients referred to the Johns Hopkins Early Psychosis Intervention Clinic (EPIC), Johns Hopkins Medicine researchers report that about half the people referred to the clinic with a schizophrenia diagnosis didn't actually have schizophrenia.

The ways of wisdom in schizophrenia
Researchers at UC San Diego School of Medicine report that persons with schizophrenia scored lower on a wisdom assessment than non-psychiatric comparison participants, but that there was considerable variability in levels of wisdom, and those with higher scores displayed fewer psychotic symptoms.

Recognizing the uniqueness of different individuals with schizophrenia
Individuals diagnosed with schizophrenia differ greatly from one another. Researchers from Radboud university medical center, along with colleagues from England and Norway, have demonstrated that very few identical brain differences are shared amongst different patients.

Resynchronizing neurons to erase schizophrenia
Today, a decisive step in understanding schizophrenia has been taken.

Read More: Schizophrenia News and Schizophrenia Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.